# Alkermes plc (ALKS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $46.10, market value $7.7 billion.

## Valuation
- **P/E (trailing): 121.3×** (5-yr avg 15.3×, 3-yr avg 15.3×). Alkermes plc trades at 121.3× trailing earnings, well above its own five-year average of 15.3×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 25.2×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 4.6×**. Each dollar of revenue is priced at 4.6×.
- **Price / book: 4.3×**. The shares trade at 4.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 41.1×**. Enterprise value is 41.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.9%** (5-yr avg 5.5%). Free cash flow equals 2.9% of the market value, below its five-year average of 5.5%, so the shares are pricier on cash than usual.
- **Earnings yield: 0.8%**. The inverse of the P/E: 0.8% of the price is earned each year.

## Profitability
- **Operating margin: 7.0%**. 7.0% of revenue is left after running the business.
- **Net margin: 16.4%**. 16.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 13.3%**. 13.3% on shareholders' equity is solid.
- **Return on invested capital: 6.5%**. Return on all capital, debt included, is 6.5%.
- **Return on assets: 2.7%**. Each dollar of assets produces 2.7% of profit.

## Growth
- **Revenue growth (1 yr): -5.2%** (3-yr 9.9%/yr, 5-yr 7.3%/yr). Revenue fell 5.2% over the last year, against 7.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -34.1%**. Earnings per share fell 34.1%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Alkermes plc holds more cash than debt.
- **Altman Z-score: 8.90**. A Z-score of 8.90 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Alkermes plc does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 59.4%** (YTD 64.8%, 3-mo 7.7%). The shares are up 59.4% over twelve months including dividends.
- **From 52-week high: -17.2%** (74.6% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 36**. An RSI of 36 is neutral.
- **Beta (1 yr): 0.79** (volatility 41%). Beta of 0.79 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALKS · Page: https://foliofundamentals.com/stocks/alks

Not investment advice.